Japan-based startup AI Medical Service Inc. (AIM) has announced 8 billion JPY (US$70 million) of financing led by SoftBank Vision Fund 2 (SVF2) and joined by existing investors Globis Capital Partners, World Innovation Lab (WiL), and Incubate Fund.

SoftBank Vision Fund is one of the largest technology investment funds in the world. It has invested $129 billion in the AI industry from the time of its inception until the end of 2021.

AIM will use the proceeds of the Series C financing round to accelerate the global adoption of endoscopic AI and finance the development of an in-house cloud-based platform.

Through its collaboration with the SoftBank Group, AIM will promote the worldwide adoption of endoscopic AI, first created in Japan using the knowledge and experience of expert endoscopists. This endoscopic AI will first be distributed on-premises, but distribution will eventually transition to a cloud platform to be developed by AIM. Realizing the vision of cloud-based endoscopic AI will allow people around the world to access the latest endoscopic medicine, contributing to vastly reduced cancer mortality.